Tagrisso 80mg Tablet

About Tagrisso 80mg Tablet

Tagrisso 80mg Tablet contains Osimertinib, a targeted anticancer medication that belongs to the protein kinase inhibitor class and is used to treat certain types of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) in adults. It works by specifically targeting and blocking abnormal EGFR proteins that promote the growth and spread of cancer cells. Tagrisso 80mg Tablet may be prescribed as an adjuvant treatment after the complete surgical removal of lung cancer to help reduce the risk of recurrence, as a first-line treatment for advanced or metastatic EGFR-positive NSCLC, or for patients whose cancer has progressed despite previous therapies. Before starting treatment, patients must undergo testing to confirm the presence of specific EGFR gene mutations that make the cancer likely to respond to Osimertinib. This medication is not recommended for children and adolescents under 18 years of age. Patients should inform their healthcare provider about any history of kidney disease, heart problems, eye disorders, or previous lung inflammation before initiating therapy. Immediate medical attention is required if symptoms such as difficulty breathing, persistent cough, fever, severe skin reactions, unusual bruising or bleeding, extreme fatigue, pale skin, or signs of infection occur during treatment. Regular monitoring throughout therapy helps ensure the safe and effective use of Tagrisso 80mg Tablet while optimizing treatment outcomes for patients with EGFR-mutated lung cancer.